As of October 13, 2025, Ozon Pharmaceuticals shares have been included in the Moscow Exchange’s first-tier quotation list following the October 9 decision. In 2025, the company conducted an SPO of 65.9 million shares and completed an additional issue, raising its free float to 14%. This met the Exchange’s first-tier criteria. The inclusion broadens the inves...

Ozon Pharmaceuticals has placed 69.1 million additional shares as part of the second stage of the SPO. Of these, 65.9 million shares were repurchased with funds from the SPO and transferred to the company's founder Pavel Aleksenko in return for those sold during the SPO. Remaining 3.2 million were acquired by the company's shareholders through the exercise o...

Ozon Pharmaceuticals is launching a new over-the-counter drug, Netugast, based on trimebutin. It is designed to eliminate pain, cramps and discomfort in the abdomen associated with functional disorders of the gastrointestinal tract and biliary tract. First 50,000 packages will be shipped to distributors in early November 2025. By the spring of 2026, the drug...

Ozon Pharmaceuticals Company is placing 78.5 million shares at ₽42 per share as part of the second stage of the SPO. Of these, 65.9 million shares will be repurchased with funds from the SPO and transferred to Pavel Aleksenko, the company's founder, in return for those sold during the SPO. Remaining 12.6 million are reserved for repurchase by the shareholder...